In 2nd quarter 2009, Colorado ranked #3 in the nation for venture capital investment in the biotechnology industry according to the PwC/NVCA MoneyTree(tm) report. Over 80% of VC investment in state companies went to bioscience companies (biotechnology – $164 million, medical devices & equipment – $8 million).
Boulder has a significant presence in the bioscience industry that emerged from research conducted at the University of Colorado at Boulder. This strength in science continues with the creation of the Biofrontiers institute at CU. This institute will focus on collaborative science breaking down traditional barriers. The Biofrontiers institute will open in 2012 and house faculty members from a variety of scientific disciplines.
Over the past forty years, the Boulder area has developed a high concentration of companies in the Pharmaceuticals and Biotechnology and Medical Devices and Instruments industry sectors. Currently, there are over 200 biosciences companies in the Boulder area, including Agilent Technologies, Amgen, Array BioPharma, Clovis Oncology, Covidien, Dharmacon, Corden Pharma, Thermo Fisher Scientific, Hospira Boulder Inc, Martek Biosciences, Indevr, OPX Biotechnologies, Pisces Molecular, and Somalogic. Local employment in the bioscience industry is six times the national average.
In addition to support through the University of Colorado, Boulder bioscience companies benefit from the area’s proximity to major medical research facilities including one of the nation’s newest and largest medical complexes featuring the Fitzsimons Life Science District and Anschutz Medical Campus and an active professional association, the Colorado Bioscience Association.
|Number of Firms||46|
|Concentration (location quotient)||5.4|
Source: University of Colorado Business Research Division (2010)